Choice of the replacement fluid during large volume plasma-exchange.
The replacement fluid used during therapeutic large volume plasma-exchange can be seen as an important factor influencing the result of such treatment. The choice includes fluids such as electrolyte solutions, gelatin, hydroxyethyl-starch, albumin and fresh frozen plasma. By evaluating the pathophysiology of the underlying disease, it is possible to choose between merely replacing the removed volume by non-protein fluids or rather to introduce plasma protein components into the patient's circulation by substituting with purified or enriched proteins such as albumin, clotting factors, antithrombin III or fresh frozen plasma. This paper analyzes the rationale for the choice of the appropriate replacement fluid taking into account pathophysiologic, pharmacologic and logistic criteria.
D001778:Blood Coagulation Disorders / Q000503:physiopathology / Q000628:therapy; D001793:Blood Preservation; D005615:Freezing; D005947:Glucose / Q000008:administration & dosage; D006801:Humans; D010949:Plasma; D010951:Plasma Exchange / Q000009:adverse effects / Q000191:economics / Q000379:methods*; D010953:Plasma Volume; D011696:Purpura, Thrombocytopenic / Q000503:physiopathology / Q000628:therapy; D012709:Serum Albumin / Q000008:administration & dosage
D012709:Serum Albumin; D005947:Glucose